Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hyperkalemia is Associated with Increased 30-Day Mortality in Hip Fracture Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Machine Learning Principles Can Improve Hip Fracture Prediction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Managing a Bone Healthy Lifestyle After Attending Multifaceted Group Education

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. An explorative literature review of the multifactorial causes of osteoporosis in epilepsy

    Research output: Contribution to journalReviewResearchpeer-review

  2. Hyponatremia and metabolic bone disease in patients with epilepsy: A cross-sectional study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Knogletæthedsmåling og biomarkører til monitorering af osteoporosebehandling

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Nicola Napoli
  • Bente L Langdahl
  • Östen Ljunggren
  • Eric Lespessailles
  • George Kapetanos
  • Tomaz Kocjan
  • Tatjana Nikolic
  • Pia Eiken
  • Helmut Petto
  • Thomas Moll
  • Erik Lindh
  • Fernando Marin
View graph of relations

This study aimed to describe clinical outcomes in patients prescribed teriparatide and followed up for 18 months after stopping the drug in real-life conditions. The Extended Forsteo® Observational Study analysed incident clinical fractures in 6-month intervals using logistic regression with repeated measures. Changes in back pain (visual analogue scale) and health-related quality of life (HRQoL; EQ-5D questionnaire) were analysed using mixed models for repeated measures. Patients were analysed if they had a post-baseline visit, regardless of whether and for how long they took teriparatide. Of 1531 patients analysed (90.7% female, mean age: 70.3 years), 76 (5.0%) never took teriparatide. Median treatment duration was 23.6 months. The adjusted odds of clinical fracture decreased by 47% in the > 12- to 18-month treatment period (p = 0.013) compared with the first 6-month period, with no statistically significant reduction in the > 18- to 24-month interval. The clinical fracture rate remained stable during the 18 months' post-teriparatide, when approximately 98% of patients took osteoporosis medication (51% bisphosphonates). Clinical vertebral fractures were reduced at every time period compared with the first 6 months. Adjusted mean back pain scores decreased and EQ-5D scores increased significantly at each post-baseline observation. In a real-life clinical setting, the risk of clinical fractures declined during 24 months of teriparatide treatment. This reduction was maintained 18 months after stopping teriparatide. In parallel, patients reported significant improvements in back pain and HRQoL. The results should be interpreted in the context of the non-controlled design of this observational study.

Original languageEnglish
JournalCalcified Tissue International
Volume103
Issue number4
Pages (from-to)359-371
ISSN0171-967X
DOIs
Publication statusPublished - 2018

ID: 54747697